This bibliography shows the most interesting papers selected from pmc PubMedCentral which were newly included in covid007_P It is available online and for download at http://www.kidney.de/write/PMCmedVIP_covid007_P.html Skewed: Nephrology, Rheumatology, Immunology, Cell Biology, Research Methods. on-topic and educational Clinical Medicine. The full table of all monthly collections is: at house-of-papers.com PMC searches were done at moremed.org
PMC7277489 10. Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action.
PMC7277771 11. Potential Application of Whole Body Vibration Exercise For Improving The Clinical Conditions of COVID-19 Infected Individuals: A Narrative Review From the World Association of Vibration Exercise Experts (WAVex) Panel.
39. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.
PMC7287752 44. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).
49. Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis.
51. Vitamin D Supplementation in Influenza and COVID-19 Infections Comment on: "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths" Nutrients 2020, 12(4), 988.
52. Reply: "Vitamin D Supplementation in Influenza and COVID-19 Infections. Comment on: Evidence That Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths Nutrients 2020, 12(4), 988".
PMC7283681 76. Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety.
{{tp|p=32401466|t=2006. Remdesivir|pdf=|usr=}} {{tp|p=32401463|t=2006. Favipiravir|pdf=|usr=}} {{tp|p=32496248|t=2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.|pdf=|usr=}} {{tp|p=32496246|t=2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.|pdf=|usr=}} {{tp|p=32496241|t=2020. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?|pdf=|usr=}} {{tp|p=32393681|t=2020. Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab.|pdf=|usr=}} {{tp|p=32468742|t=2020. Reply: Vitamin C as a Possible Therapy for COVID-19.|pdf=|usr=}} {{tp|p=32410417|t=2020. Vitamin C as a Possible Therapy for COVID-19.|pdf=|usr=}} {{tp|p=32476308|t=2020. Empirical Treatment and Prevention of COVID-19.|pdf=|usr=}} {{tp|p=32466136|t=2020. Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action.|pdf=|usr=}} {{tp|p=32455961|t=2020. Potential Application of Whole Body Vibration Exercise For Improving The Clinical Conditions of COVID-19 Infected Individuals: A Narrative Review From the World Association of Vibration Exercise Experts (WAVex) Panel.|pdf=|usr=}} {{tp|p=32486229|t=2020. Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations.|pdf=|usr=}} {{tp|p=32481690|t=2020. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases.|pdf=|usr=}} {{tp|p=32471278|t=2020. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.|pdf=|usr=}} {{tp|p=32471272|t=2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?|pdf=|usr=}} {{tp|p=32471205|t=2020. Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition.|pdf=|usr=}} {{tp|p=32455534|t=2020. Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds.|pdf=|usr=}} {{tp|p=32443911|t=2020. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.|pdf=|usr=}} {{tp|p=32429572|t=2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.|pdf=|usr=}} {{tp|p=32429099|t=2020. Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19.|pdf=|usr=}} {{tp|p=32408699|t=2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.|pdf=|usr=}} {{tp|p=32463348|t=2020. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.|pdf=|usr=}} {{tp|p=32463308|t=2020. Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?|pdf=|usr=}} {{tp|p=32392184|t=2020. Clinical trials for COVID-19 should include sex as a variable.|pdf=|usr=}} {{tp|p=32456123|t=2020. Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.|pdf=|usr=}} {{tp|p=32474406|t=2020. The rediscovery of hydroxychloroquine in allergic diseases in the COVID-19 era.|pdf=|usr=}} {{tp|p=32457038|t=2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.|pdf=|usr=}} {{tp|p=32451353|t=2020. Evidence of Protective Effect of Hydroxychloroquine on COVID-19.|pdf=|usr=}} {{tp|p=32423974|t=2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?|pdf=|usr=}} {{tp|p=32393664|t=2020. Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials.|pdf=|usr=}} {{tp|p=32475851|t=2020. COVID-19: Stay Cool toward Corticosteroids.|pdf=|usr=}} {{tp|p=32475104|t=2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.|pdf=|usr=}} {{tp|p=32293020|t=2020. Palliativ farmakologisk behandling vid svar covid-19.|pdf=|usr=}} {{tp|p=32444382|t=2020. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.|pdf=|usr=}} {{tp|p=32442946|t=2020. inverted question markBCG versus COVID-19?|pdf=|usr=}} {{tp|p=32442941|t=2020. Hidroxicloroquina. Mensajes desde la cardiologia en tiempos de pandemia por coronavirus.|pdf=|usr=}} {{tp|p=32490889|t=2020. Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach.|pdf=|usr=}} {{tp|p=32397399|t=2020. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).|pdf=|usr=}} {{tp|p=32162896|t=2020. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.|pdf=|usr=}} {{tp|p=32407051|t=2020. Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19?|pdf=|usr=}} {{tp|p=32485894|t=2020. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.|pdf=|usr=}} {{tp|p=32455942|t=2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.|pdf=|usr=}} {{tp|p=32429580|t=2020. Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).|pdf=|usr=}} {{tp|p=32408547|t=2020. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).|pdf=|usr=}} {{tp|p=32486364|t=2020. Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.|pdf=|usr=}} {{tp|p=32495926|t=2020. Does amantadine have a protective effect against COVID-19?|pdf=|usr=}} {{tp|p=32397511|t=2020. 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2.|pdf=|usr=}} {{tp|p=32486488|t=2020. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.|pdf=|usr=}} {{tp|p=32471251|t=2020. Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis.|pdf=|usr=}} {{tp|p=32438620|t=2020. COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation.|pdf=|usr=}} {{tp|p=32492809|t=2020. Vitamin D Supplementation in Influenza and COVID-19 Infections Comment on: "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths" Nutrients 2020, 12(4), 988.|pdf=|usr=}} {{tp|p=32492787|t=2020. Reply: "Vitamin D Supplementation in Influenza and COVID-19 Infections. Comment on: Evidence That Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths Nutrients 2020, 12(4), 988".|pdf=|usr=}} {{tp|p=32418757|t=2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?|pdf=|usr=}} {{tp|p=32471171|t=2020. Excess Ascorbate is a Chemical Stress Agent against Proteins and Cells.|pdf=|usr=}} {{tp|p=32423027|t=2020. COVID-19: An Update About the Discovery Clinical Trial.|pdf=|usr=}} {{tp|p=32423024|t=2020. The Rationale for Potential Pharmacotherapy of COVID-19.|pdf=|usr=}} {{tp|p=32434254|t=2020. Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.|pdf=|usr=}} {{tp|p=32470046|t=2020. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light.|pdf=|usr=}} {{tp|p=32497149|t=2020. In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction.|pdf=|usr=}} {{tp|p=32505040|t=2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.|pdf=|usr=}} {{tp|p=32491112|t=2020. Does Vitamin D play a role in the management of Covid-19 in Brazil?|pdf=|usr=}} {{tp|p=32381590|t=2020. Ethics of controlled human infection to address COVID-19.|pdf=|usr=}} {{tp|p=32472653|t=2020. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.|pdf=|usr=}} {{tp|p=32472939|t=2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.|pdf=|usr=}} {{tp|p=32448818|t=2020. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.|pdf=|usr=}} {{tp|p=32447783|t=2020. Convalescent plasma for COVID-19: Back to the future.|pdf=|usr=}} {{tp|p=32449169|t=2020. How did we rapidly implement a convalescent plasma program?|pdf=|usr=}} {{tp|p=32449171|t=2020. COVID-19: are neutralizing antibodies neutralizing enough?|pdf=|usr=}} {{tp|p=32428966|t=2020. COVID-19 convalescent plasma donor recruitment: beware the Faustian bargains.|pdf=|usr=}} {{tp|p=32395792|t=2020. COVID-19: Main therapeutic options.|pdf=|usr=}} {{tp|p=32507409|t=2020. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.|pdf=|usr=}} {{tp|p=32442105|t=2020. The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.|pdf=|usr=}} {{tp|p=32397182|t=2020. Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development.|pdf=|usr=}} {{tp|p=32486283|t=2020. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.|pdf=|usr=}} {{tp|p=32397643|t=2020. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.|pdf=|usr=}} {{tp|p=32464700|t=2020. Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety.|pdf=|usr=}}
77. Current Perspective of Antiviral Strategies against COVID-19.
{{tp|p=32485102|t=2020. Current Perspective of Antiviral Strategies against COVID-19.|pdf=|usr=}} {{tp|p=32369098|t=2020. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).|pdf=|usr=}} {{tp|p=32398379|t=2020. Convalescent plasma for patients with COVID-19.|pdf=|usr=}} {{tp|p=32398378|t=2020. Get rid of the bad first: Therapeutic plasma exchange with convalescent plasma for severe COVID-19.|pdf=|usr=}} {{tp|p=32398377|t=2020. Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19.|pdf=|usr=}} {{tp|p=32438839|t=2020. Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?|pdf=|usr=}} {{tp|p=32462848|t=2020. Interleukine-1 et blocage du COVID-19.|pdf=|usr=}} {{tp|p=32348059|t=2020. COVID-19, dans les brouillards de l'hydroxychloroquine (4).|pdf=|usr=}} {{tp|p=32320161|t=2020. Covid-19, dans les brouillards de l'hydroxychloroquine (3).|pdf=|usr=}} {{tp|p=32495979|t=2020. Emergence of novel coronavirus and progress toward treatment and vaccine.|pdf=|usr=}} {{tp|p=32512588|t=2020. Challenges in the Production of Convalescent Hyperimmune Plasma in the Age of COVID-19.|pdf=|usr=}} {{tp|p=32453251|t=2020. Extracorporeal Hemoadsorption: An Option for COVID-19 Associated Cytokine Storm Syndrome.|pdf=|usr=}} {{tp|p=32496422|t=2020. Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis.|pdf=|usr=}} {{tp|p=32500793|t=2020. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.|pdf=|usr=}} {{tp|p=32380908|t=2020. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.|pdf=|usr=}} {{tp|p=32510799|t=2020. The Application Of Plasmapheresis For Covid-19 Patients.|pdf=|usr=}} {{tp|p=32501607|t=2020. Selective C-reactive protein (CRP) apheresis for Covid-19 patients suffering from organ damage.|pdf=|usr=}} {{tp|p=32433189|t=2020. Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19): how to act.|pdf=|usr=}} {{tp|p=32402475|t=2020. Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data.|pdf=|usr=}} {{tp|p=32473596|t=2020. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.|pdf=|usr=}} {{tp|p=32491199|t=2020. Feasibility of a Pilot Program for COVID-19 Convalescent Plasma Collection in Wuhan, China.|pdf=|usr=}} {{tp|p=32500936|t=2020. Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab.|pdf=|usr=}} {{tp|p=32400382|t=2020. [Brug af hydroxychloroquin til COVID-19].|pdf=|usr=}} {{tp|p=32400380|t=2020. [Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].|pdf=|usr=}} {{tp|p=32391669|t=2020. [Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab].|pdf=|usr=}} {{tp|p=32391667|t=2020. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].|pdf=|usr=}} {{tp|p=32391659|t=2020. [Pharmaceutical care for severe and critically ill patients with COVID-19].|pdf=|usr=}} {{tp|p=32458599|t=2020. [Pharmacological characteristics of chloroquine and suggestions for its use in treatment of coronavirus disease 2019 (COVID-19)].|pdf=|usr=}} {{tp|p=32489024|t=2020. [Discovery of intervention effect of Chinese herbal formulas on COVID-19 pulmonary fibrosis treated by VEGFR and FGFR inhibitors].|pdf=|usr=}} {{tp|p=32450629|t=2020. [Application of convalescent plasma therapy on novel coronavirus infection].|pdf=|usr=}} {{tp|p=32034899|t=2020. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].|pdf=|usr=}} {{tp|p=32023685|t=2020. [Potential antiviral therapeutics for 2019 Novel Coronavirus].|pdf=|usr=}} {{tp|p=32075365|t=2020. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].|pdf=|usr=}} {{tp|p=32057209|t=2020. [Pharmacotherapeutics for the New Coronavirus Pneumonia].|pdf=|usr=}} {{tp|p=32397700|t=2020. [Analysis of application of herd immunity as a control strategy for COVID-19].|pdf=|usr=}} {{tp|p=32388937|t=2020. [Real-world efficacy and safety of lopinavir/ritonavir and arbidol in treating with COVID-19 : an observational cohort study].|pdf=|usr=}}
113. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
116. Targeting SARS-CoV-2 Receptors as a Means for Reducing Infectivity and Improving Antiviral and Immune Response: An Algorithm-based Method For Overcoming Resistance To Antiviral Agents.
PMC7280586 125. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.
PMC7284148 128. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2.
PMC7272169 130. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.
PMC7229724 135. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.
{{tp|p=32473600|t=2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.|pdf=|usr=}} {{tp|p=32491981|t=2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.|pdf=|usr=}} {{tp|p=32487283|t=2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.|pdf=|usr=}} {{tp|p=32490731|t=2020. Targeting SARS-CoV-2 Receptors as a Means for Reducing Infectivity and Improving Antiviral and Immune Response: An Algorithm-based Method For Overcoming Resistance To Antiviral Agents.|pdf=|usr=}} {{tp|p=32432977|t=2020. Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture.|pdf=|usr=}} {{tp|p=32403995|t=2020. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.|pdf=|usr=}} {{tp|p=32499303|t=2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.|pdf=|usr=}} {{tp|p=32496239|t=2020. Potential pharmacological agents for COVID-19.|pdf=|usr=}} {{tp|p=32496238|t=2020. COVID-19 vaccine development and the way forward.|pdf=|usr=}} {{tp|p=32496237|t=2020. AYUSH for COVID-19: Science or Superstition?|pdf=|usr=}} {{tp|p=32454489|t=2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.|pdf=|usr=}} {{tp|p=32392562|t=2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.|pdf=|usr=}} {{tp|p=32436995|t=2020. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.|pdf=|usr=}} {{tp|p=32436994|t=2020. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.|pdf=|usr=}} {{tp|p=32510105|t=2020. COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics.|pdf=|usr=}} {{tp|p=32476594|t=2020. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2.|pdf=|usr=}} {{tp|p=32462719|t=2020. Nutrition Therapy in Critically Ill Patients with Coronavirus Disease (COVID-19).|pdf=|usr=}} {{tp|p=32505467|t=2020. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.|pdf=|usr=}} {{tp|p=32505245|t=2020. COVID-19 vaccine development pipeline gears up.|pdf=|usr=}} {{tp|p=32505909|t=2020. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.|pdf=|usr=}} {{tp|p=32512490|t=2020. Potential role of zinc supplementation in prophylaxis and treatment of COVID-19.|pdf=|usr=}} {{tp|p=32492560|t=2020. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?|pdf=|usr=}} {{tp|p=32460209|t=2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.|pdf=|usr=}} {{tp|p=32512493|t=2020. The effects of allium sativum on immunity within the scope of COVID-19 infection.|pdf=|usr=}} {{tp|p=32454510|t=2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.|pdf=|usr=}} {{tp|p=32492996|t=2020. Management of nutritional consultations in local clinics during SARS-CoV-2 pandemic.|pdf=|usr=}} {{tp|p=32492298|t=2020. Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence.|pdf=|usr=}} {{tp|p=32492293|t=2020. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.|pdf=|usr=}} {{tp|p=32487990|t=2020. Modeling mitigation of influenza epidemics by baloxavir.|pdf=|usr=}} {{tp|p=32506067|t=2020. Covid-19 and Exercise-Induced Immunomodulation.|pdf=|usr=}} {{tp|p=32446287|t=2020. Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19.|pdf=|usr=}} {{tp|p=32468635|t=2020. Food as medicine: a possible preventive measure against coronavirus disease (COVID-19).|pdf=|usr=}} {{tp|p=32442323|t=2020. Curcumin as a potential treatment for COVID-19.|pdf=|usr=}} {{tp|p=32430996|t=2020. Potential effects of curcumin in the treatment of COVID-19 infection.|pdf=|usr=}} {{tp|p=32424845|t=2020. Artemisia annua: Trials are needed for COVID-19.|pdf=|usr=}} {{tp|p=32503877|t=2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.|pdf=|usr=}}
149. A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19.
150. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.
151. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.
159. HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern.
164. A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.
167. Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings.
{{tp|p=32510169|t=2020. A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19.|pdf=|usr=}} {{tp|p=32501538|t=2020. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.|pdf=|usr=}} {{tp|p=32492211|t=2020. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.|pdf=|usr=}} {{tp|p=32492210|t=2020. Tocilizumab Administration in Patients with SARS-CoV-2 Infection: Subcutaneous Injection versus Intravenous Infusion.|pdf=|usr=}} {{tp|p=32492205|t=2020. COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.|pdf=|usr=}} {{tp|p=32492200|t=2020. Remdesivir and Tocilizumab: Mix or Match.|pdf=|usr=}} {{tp|p=32484930|t=2020. ''Tociluzumab challenge: A series of cytokine storm therapy experience in hospitalized Covid-19 pneumonia patients''.|pdf=|usr=}} {{tp|p=32484915|t=2020. Feasibility of Tocilizumab in ICU patients with COVID-19.|pdf=|usr=}} {{tp|p=32421836|t=2020. Potential pharmacological perspectives for the treatment/prevention of the SARS-COV-2 infection in opioid dependent patients.|pdf=|usr=}} {{tp|p=32496442|t=2020. Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?|pdf=|usr=}} {{tp|p=32490532|t=2020. HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern.|pdf=|usr=}} {{tp|p=32506862|t=2020. Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients.|pdf=|usr=}} {{tp|p=32427774|t=2020. Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.|pdf=|usr=}} {{tp|p=32427277|t=2020. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.|pdf=|usr=}} {{tp|p=32495940|t=2020. Probiotics and COVID-19: is there any link?|pdf=|usr=}} {{tp|p=32504751|t=2020. A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.|pdf=|usr=}} {{tp|p=32505910|t=2020. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1beta/neutrophil extracellular traps feedback loop.|pdf=|usr=}} {{tp|p=32502901|t=2020. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.|pdf=|usr=}} {{tp|p=32498009|t=2020. Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings.|pdf=|usr=}} {{tp|p=32505070|t=2020. Nebulized Lidocaine in COVID-19, An Hypothesis.|pdf=|usr=}} {{tp|p=32463026|t=2020. A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes.|pdf=|usr=}} {{tp|p=32506110|t=2020. Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences.|pdf=|usr=}} {{tp|p=32459919|t=2020. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.|pdf=|usr=}} {{tp|p=32369285|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=}} {{tp|p=32369284|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=}} {{tp|p=32369283|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=}} {{tp|p=32369282|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=}} {{tp|p=32369281|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=}} {{tp|p=32412709|t=2020. Compassionate Use of Remdesivir in Covid-19. Reply.|pdf=|usr=}} {{tp|p=32412708|t=2020. Compassionate Use of Remdesivir in Covid-19.|pdf=|usr=}} {{tp|p=32412707|t=2020. Compassionate Use of Remdesivir in Covid-19.|pdf=|usr=}} {{tp|p=32412706|t=2020. Compassionate Use of Remdesivir in Covid-19.|pdf=|usr=}} {{tp|p=32412705|t=2020. Compassionate Use of Remdesivir in Covid-19.|pdf=|usr=}} {{tp|p=32438383|t=2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.|pdf=|usr=}} {{tp|p=32325475|t=2020. The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections.|pdf=|usr=}} {{tp|p=32472069|t=2020. Questions remain following first COVID-19 vaccine results.|pdf=|usr=}} {{tp|p=32393915|t=2020. Biggest COVID-19 trial tests repurposed drugs first.|pdf=|usr=}} {{tp|p=32417850|t=2020. Drug researchers pursue new lines of attack against COVID-19.|pdf=|usr=}} {{tp|p=32415300|t=2020. Biotech companies prepare for COVID-19 downturn.|pdf=|usr=}} {{tp|p=32415251|t=2020. 15 drugs being tested to treat COVID-19 and how they would work.|pdf=|usr=}} {{tp|p=32488217|t=2020. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.|pdf=|usr=}} {{tp|p=32382072|t=2020. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.|pdf=|usr=}} {{tp|p=32422645|t=2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.|pdf=|usr=}} {{tp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.|pdf=|usr=}} {{tp|p=32415276|t=2020. The sprint to solve coronavirus protein structures - and disarm them with drugs.|pdf=|usr=}} {{tp|p=32409766|t=2020. Dozens of coronavirus drugs are in development - what happens next?|pdf=|usr=}} {{tp|p=32405023|t=2020. Coronavirus drugs trials must get bigger and more collaborative.|pdf=|usr=}} {{tp|p=32203367|t=2020. Coronavirus vaccines: five key questions as trials begin.|pdf=|usr=}} {{tp|p=32512579|t=2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.|pdf=|usr=}} {{tp|p=32504019|t=2020. The coronavirus outbreak could make it quicker and easier to trial drugs.|pdf=|usr=}} {{tp|p=32424192|t=2020. CRISPR tool scales up to interrogate a huge line-up of viral suspects.|pdf=|usr=}} {{tp|p=32273621|t=2020. If a coronavirus vaccine arrives, can the world make enough?|pdf=|usr=}} {{tp|p=32299148|t=2020. Considerations for Obesity, Vitamin D, and Physical Activity Amid the COVID-19 Pandemic.|pdf=|usr=}} {{tp|p=32324363|t=2020. [A szerzett hosszu-QT-szindroma veszelye a koronavirus-jarvany idejen. Fokuszban a hidroxiklorokin]|pdf=|usr=}} {{tp|p=32324361|t=2020. [Farmakoterapias lehetosegek SARS-CoV-2-fertozes/COVID-19-betegseg eseten]|pdf=|usr=}} {{tp|p=32427644|t=2020. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines: Setting Expectations Appropriately.|pdf=|usr=}} {{tp|p=32398330|t=2020. A Call for Pediatric COVID-19 Clinical Trials.|pdf=|usr=}} {{tp|p=32423342|t=2020. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?|pdf=|usr=}} {{tp|p=32393419|t=2020. Recent advances of therapeutic targets and potential drugs of COVID-19.|pdf=|usr=}} {{tp|p=32476189|t=2020. SARS-CoV-2 pandemic and Vitamin D deficiency-A double trouble.|pdf=|usr=}} {{tp|p=32472655|t=2020. Cytokine storm in COVID-19 and parthenolide: preclinical evidence.|pdf=|usr=}} {{tp|p=32501634|t=2020. Can Hypericum perforatum (SJW) prevent cytokine storm in COVID-19 patients?|pdf=|usr=}} {{tp|p=32488956|t=2020. Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19?|pdf=|usr=}} {{tp|p=32496926|t=2020. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.|pdf=|usr=}} {{tp|p=32439730|t=2020. Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?|pdf=|usr=}} {{tp|p=32295814|t=2020. Hydroxychloroquine and covid-19.|pdf=|usr=}} {{tp|p=32116200|t=2020. COVID-19: Perspectives on the Potential Novel Global Threat.|pdf=|usr=}} {{tp|p=32472681|t=2020. Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease.|pdf=|usr=}} {{tp|p=32385052|t=2020. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.|pdf=|usr=}} {{tp|p=32381697|t=2020. The race is on for antibodies that stop the new coronavirus.|pdf=|usr=}} {{tp|p=32381692|t=2020. Combination prevention for COVID-19.|pdf=|usr=}} {{tp|p=32393526|t=2020. A strategic approach to COVID-19 vaccine R&D.|pdf=|usr=}} {{tp|p=32385100|t=2020. Rapid COVID-19 vaccine development.|pdf=|usr=}} {{tp|p=32461212|t=2020. Reducing transmission of SARS-CoV-2.|pdf=|usr=}} {{tp|p=32385101|t=2020. Rapid repurposing of drugs for COVID-19.|pdf=|usr=}} {{tp|p=32327575|t=2020. NIH organizes hunt for drugs.|pdf=|usr=}}
225. Practical aspects of targeting IL-6 in COVID-19 disease.
231. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.
232. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.
PMC7266779 240. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.
PMC7284143 247. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M(pro)) of SARS-CoV-2 and inhibit its activity.
PMC7284146 250. Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations.
PMC7280598 266. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old.
PMC7270883 271. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
{{tp|p=32409439|t=2020. Practical aspects of targeting IL-6 in COVID-19 disease.|pdf=|usr=}} {{tp|p=32409433|t=2020. Antivirals for COVID-19.|pdf=|usr=}} {{tp|p=32456769|t=2020. Early tocilizumab treatment could improve survival among COVID-19 patients.|pdf=|usr=}} {{tp|p=32456767|t=2020. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease?|pdf=|usr=}} {{tp|p=32452345|t=2020. The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart.|pdf=|usr=}} {{tp|p=32490931|t=2020. 17beta-Estradiol, a potential ally to alleviate SARS-CoV-2 infection.|pdf=|usr=}} {{tp|p=32444482|t=2020. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.|pdf=|usr=}} {{tp|p=32409522|t=2020. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.|pdf=|usr=}} {{tp|p=32420637|t=2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.|pdf=|usr=}} {{tp|p=32294756|t=2020. Intervencoes nao farmacologicas para o enfrentamento a epidemia da COVID-19 no Brasil.|pdf=|usr=}} {{tp|p=32441894|t=2020. Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.|pdf=|usr=}} {{tp|p=32438473|t=2020. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.|pdf=|usr=}} {{tp|p=32437587|t=2020. COVID-19 vaccines: knowing the unknown.|pdf=|usr=}} {{tp|p=32460358|t=2020. The early landscape of COVID-19 vaccine development in the UK and rest of the world.|pdf=|usr=}} {{tp|p=32496938|t=2020. A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.|pdf=|usr=}} {{tp|p=32512271|t=2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.|pdf=|usr=}} {{tp|p=32512383|t=2020. Mitigating Coronavirus-Induced Acute Respiratory Distress Syndrome by Radiotherapy.|pdf=|usr=}} {{tp|p=32448039|t=2020. In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2.|pdf=|usr=}} {{tp|p=32448098|t=2020. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.|pdf=|usr=}} {{tp|p=32448034|t=2020. Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches.|pdf=|usr=}} {{tp|p=32448085|t=2020. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.|pdf=|usr=}} {{tp|p=32452282|t=2020. Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease.|pdf=|usr=}} {{tp|p=32431217|t=2020. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M(pro)) of SARS-CoV-2 and inhibit its activity.|pdf=|usr=}} {{tp|p=32419646|t=2020. Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study.|pdf=|usr=}} {{tp|p=32410504|t=2020. Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2-a molecular dynamic study.|pdf=|usr=}} {{tp|p=32396767|t=2020. Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations.|pdf=|usr=}} {{tp|p=32469418|t=2020. Evaluation of potential therapeutic options for COVID-19.|pdf=|usr=}} {{tp|p=32445400|t=2020. Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?|pdf=|usr=}} {{tp|p=32441805|t=2020. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.|pdf=|usr=}} {{tp|p=32437001|t=2020. Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope".|pdf=|usr=}} {{tp|p=32434282|t=2020. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?|pdf=|usr=}} {{tp|p=32472779|t=2020. Food protein-derived antihypertensive peptides in the COVID-19 pandemic: friends of foes?|pdf=|usr=}} {{tp|p=32508069|t=2020. Therapeutic Temperature Modulation for a Critically Ill Patient with COVID-19.|pdf=|usr=}} {{tp|p=32470199|t=2020. Metformin use amid coronavirus disease 2019 pandemic.|pdf=|usr=}} {{tp|p=32470160|t=2020. Glucocorticoid therapy delays the clearance of SARS-CoV-2 RNA in an asymptomatic COVID-19 patient.|pdf=|usr=}} {{tp|p=32470146|t=2020. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis.|pdf=|usr=}} {{tp|p=32462717|t=2020. COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.|pdf=|usr=}} {{tp|p=32458502|t=2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.|pdf=|usr=}} {{tp|p=32458475|t=2020. Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic.|pdf=|usr=}} {{tp|p=32458488|t=2020. Potential negative effects of the free use of chloroquine to manage COVID-19 in Colombia.|pdf=|usr=}} {{tp|p=32458425|t=2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.|pdf=|usr=}} {{tp|p=32441786|t=2020. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old.|pdf=|usr=}} {{tp|p=32437024|t=2020. Convalescent plasma therapy: A passive therapy for an aggressive COVID-19.|pdf=|usr=}} {{tp|p=32437019|t=2020. Baricitinib: A chance to treat COVID-19?|pdf=|usr=}} {{tp|p=32437014|t=2020. A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19.|pdf=|usr=}} {{tp|p=32463459|t=2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.|pdf=|usr=}} {{tp|p=32492084|t=2020. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.|pdf=|usr=}}
272. Potential Unconventional Medicines for the Treatment of SARS-CoV-2.
273. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
274. An open label cluster randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 (ARCHAIC) - Protocol publication.
279. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.
281. Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.
286. SARS-CoV-2, from its current highly contagious spreading toward the global development of an effective and safe vaccine: challenges and uncertainties.
303. Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol.
310. Docking study of Chloroquine and Hydroxychloroquine interaction with SARS-CoV-2 spike glycoprotein-An in silico insight into the comparative efficacy of repurposing antiviral drugs.
314. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.
316. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment.
327. Serum concentrations of interleukin-6 (IL-6) in the general adult population: possible implications for anti-IL-6 therapy in SARS-Cov-2 infection and IL-6-related diseases.
{{tp|p=32428941|t=2020. Potential Unconventional Medicines for the Treatment of SARS-CoV-2.|pdf=|usr=}} {{tp|p=32498081|t=2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).|pdf=|usr=}} {{tp|p=32474918|t=2020. An open label cluster randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 (ARCHAIC) - Protocol publication.|pdf=|usr=}} {{tp|p=32500556|t=2020. Doubtful precipitation of hemolysis by hydroxychloroquine in glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection.|pdf=|usr=}} {{tp|p=32499314|t=2020. Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19.|pdf=|usr=}} {{tp|p=32449669|t=2020. A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics.|pdf=|usr=}} {{tp|p=32432527|t=2020. Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence.|pdf=|usr=}} {{tp|p=32495917|t=2020. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.|pdf=|usr=}} {{tp|p=32495916|t=2020. Tocilizumab in the treatment of a critical COVID-19 patient: a case report.|pdf=|usr=}} {{tp|p=32495848|t=2020. Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.|pdf=|usr=}} {{tp|p=32380868|t=2020. Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?|pdf=|usr=}} {{tp|p=32406282|t=2020. Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces.|pdf=|usr=}} {{tp|p=32427004|t=2020. Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?|pdf=|usr=}} {{tp|p=32452701|t=2020. An up-to-date overview of computational polypharmacology in modern drug discovery.|pdf=|usr=}} {{tp|p=32442040|t=2020. SARS-CoV-2, from its current highly contagious spreading toward the global development of an effective and safe vaccine: challenges and uncertainties.|pdf=|usr=}} {{tp|p=32447996|t=2020. Treatments in the COVID-19 pandemic: an update on clinical trials.|pdf=|usr=}} {{tp|p=32475183|t=2020. Does lopinavir measure up in the treatment of COVID-19?|pdf=|usr=}} {{tp|p=32348165|t=2020. Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.|pdf=|usr=}} {{tp|p=32282262|t=2020. Treatment considerations for coronavirus (COVID-19).|pdf=|usr=}} {{tp|p=32469280|t=2020. COVID-19: Gene Transfer to the Rescue?|pdf=|usr=}} {{tp|p=32423245|t=2020. The Impact of the COVID-19 Pandemic on the Biotech Industry.|pdf=|usr=}} {{tp|p=32212981|t=2020. A Message to Our Community in the Midst of the COVID-19 Pandemic.|pdf=|usr=}} {{tp|p=32501133|t=2020. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?|pdf=|usr=}} {{tp|p=32503817|t=2020. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.|pdf=|usr=}} {{tp|p=32503816|t=2020. Oral Methioninase for Covid-19 Methionine-restriction Therapy.|pdf=|usr=}} {{tp|p=32503815|t=2020. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.|pdf=|usr=}} {{tp|p=32503814|t=2020. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.|pdf=|usr=}} {{tp|p=32449676|t=2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.|pdf=|usr=}} {{tp|p=32468014|t=2020. Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review).|pdf=|usr=}} {{tp|p=32401694|t=2020. Flying by the seat of our pants: is low dose radiation therapy for COVID-19 an option?|pdf=|usr=}} {{tp|p=32474476|t=2020. Risk of using hydroxychloroquine as a treatment of COVID-19.|pdf=|usr=}} {{tp|p=32468508|t=2020. Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol.|pdf=|usr=}} {{tp|p=32310670|t=2020. Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis.|pdf=|usr=}} {{tp|p=32473020|t=2020. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.|pdf=|usr=}} {{tp|p=32457980|t=2020. Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report.|pdf=|usr=}} {{tp|p=32443151|t=2020. Lopinavir pharmacokinetics in COVID-19 patients.|pdf=|usr=}} {{tp|p=32462858|t=2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.|pdf=|usr=}} {{tp|p=32469279|t=2020. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.|pdf=|usr=}} {{tp|p=32469265|t=2020. Docking study of Chloroquine and Hydroxychloroquine interaction with SARS-CoV-2 spike glycoprotein-An in silico insight into the comparative efficacy of repurposing antiviral drugs.|pdf=|usr=}} {{tp|p=32462988|t=2020. A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem).|pdf=|usr=}} {{tp|p=32406317|t=2020. Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach.|pdf=|usr=}} {{tp|p=32475223|t=2020. Antiviral effects of probiotic metabolites on COVID-19.|pdf=|usr=}} {{tp|p=32462970|t=2020. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.|pdf=|usr=}} {{tp|p=32456606|t=2020. Synergistic effect of vitamin D and remdesivir can fight COVID-19.|pdf=|usr=}} {{tp|p=32462996|t=2020. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment.|pdf=|usr=}} {{tp|p=32476576|t=2020. Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies.|pdf=|usr=}} {{tp|p=32476574|t=2020. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms.|pdf=|usr=}} {{tp|p=32485061|t=2020. Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.|pdf=|usr=}} {{tp|p=32487869|t=2020. COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?|pdf=|usr=}} {{tp|p=32433345|t=2020. The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2.|pdf=|usr=}} {{tp|p=32511763|t=2020. Colchicine and COVID-19.|pdf=|usr=}} {{tp|p=32473011|t=2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.|pdf=|usr=}} {{tp|p=32504739|t=2020. Interleukin-17: A potential therapeutic target in COVID-19.|pdf=|usr=}} {{tp|p=32473010|t=2020. TPE-nAbs combination therapy for severe COVID-19.|pdf=|usr=}} {{tp|p=32220033|t=2020. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).|pdf=|usr=}} {{tp|p=32500858|t=2020. Serum concentrations of interleukin-6 (IL-6) in the general adult population: possible implications for anti-IL-6 therapy in SARS-Cov-2 infection and IL-6-related diseases.|pdf=|usr=}} {{tp|p=32511912|t=2020. COVID-19: Drug targets and potential treatments.|pdf=|usr=}} {{tp|p=32469301|t=2020. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.|pdf=|usr=}} {{tp|p=32380930|t=2020. Chloroquine and the potential adverse outcome in undiagnosed G6PD-deficient cases infected with COVID-19.|pdf=|usr=}} {{tp|p=32472703|t=2020. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients.|pdf=|usr=}} {{tp|p=32427773|t=2020. Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series.|pdf=|usr=}} {{tp|p=32364561|t=2020. Randomized Clinical Trials and COVID-19: Managing Expectations.|pdf=|usr=}} {{tp|p=32463427|t=2020. Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic.|pdf=|usr=}} {{tp|p=32453363|t=2020. No Benefit for Lopinavir-Ritonavir in Severe COVID-19.|pdf=|usr=}} {{tp|p=32492105|t=2020. A Randomized Trial of Convalescent Plasma for COVID-19-Potentially Hopeful Signals.|pdf=|usr=}}
PMC7275134 337. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.
PMC7277789 346. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.
PMC7250695 351. Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".
PMC7280623 357. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.
PMC7280633 366. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
{{tp|p=32506195|t=2020. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.|pdf=|usr=}} {{tp|p=32438459|t=2020. Efficacy, safety and cost-effectiveness of hydroxychloroquine in children with COVID-19: A call for evidence.|pdf=|usr=}} {{tp|p=32463794|t=2020. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.|pdf=|usr=}} {{tp|p=32432810|t=2020. Letter: does vitamin D have a potential role against COVID-19?|pdf=|usr=}} {{tp|p=32434272|t=2020. COVID-19Clinical trials: quality matters more than quantity.|pdf=|usr=}} {{tp|p=32384798|t=2020. Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19.|pdf=|usr=}} {{tp|p=32464736|t=2020. A simulation training course for family medicine residents in China managing COVID-19.|pdf=|usr=}} {{tp|p=32505821|t=2020. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.|pdf=|usr=}} {{tp|p=32485858|t=2020. Javamide-II Inhibits IL-6 without Significant Impact on TNF-alpha and IL-1beta in Macrophage-Like Cells.|pdf=|usr=}} {{tp|p=32455629|t=2020. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.|pdf=|usr=}} {{tp|p=32441299|t=2020. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy.|pdf=|usr=}} {{tp|p=32398343|t=2020. Should azithromycin be used to treat COVID-19? A rapid review.|pdf=|usr=}} {{tp|p=32464624|t=2020. Cytokine Blood Filtration Responses in COVID-19.|pdf=|usr=}} {{tp|p=32454500|t=2020. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.|pdf=|usr=}} {{tp|p=32453693|t=2020. Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".|pdf=|usr=}} {{tp|p=32453692|t=2020. Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.|pdf=|usr=}} {{tp|p=32453687|t=2020. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.|pdf=|usr=}} {{tp|p=32503874|t=2020. Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials.|pdf=|usr=}} {{tp|p=32267762|t=2020. Research towards treating COVID-19.|pdf=|usr=}} {{tp|p=32453903|t=2020. Efficacy of therapeutic plasma exchange in severe COVID-19 patients.|pdf=|usr=}} {{tp|p=32438450|t=2020. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.|pdf=|usr=}} {{tp|p=32433778|t=2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.|pdf=|usr=}} {{tp|p=32442317|t=2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).|pdf=|usr=}} {{tp|p=32441783|t=2020. A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19).|pdf=|usr=}} {{tp|p=32441764|t=2020. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?|pdf=|usr=}} {{tp|p=32424836|t=2020. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.|pdf=|usr=}} {{tp|p=32449802|t=2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?|pdf=|usr=}} {{tp|p=32512007|t=2020. Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.|pdf=|usr=}} {{tp|p=32445484|t=2020. A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19.|pdf=|usr=}} {{tp|p=32438446|t=2020. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.|pdf=|usr=}} {{tp|p=32508009|t=2020. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.|pdf=|usr=}} {{tp|p=32441462|t=2020. Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.|pdf=|usr=}} {{tp|p=32511867|t=2020. Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID-19 Clinical Trials.|pdf=|usr=}} {{tp|p=32418327|t=2020. Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.|pdf=|usr=}} {{tp|p=32449939|t=2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection.|pdf=|usr=}}
372. Sofosbuvir as a potential option for the treatment of COVID-19.
399. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
410. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients.
{{tp|p=32420958|t=2020. Sofosbuvir as a potential option for the treatment of COVID-19.|pdf=|usr=}} {{tp|p=32420947|t=2020. Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now).|pdf=|usr=}} {{tp|p=32420936|t=2020. Treatments for COVID-19: emerging drugs against the coronavirus.|pdf=|usr=}} {{tp|p=32425152|t=2020. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.|pdf=|usr=}} {{tp|p=32506621|t=2020. Drugs being investigated for children with COVID-19.|pdf=|usr=}} {{tp|p=32468505|t=2020. Association between low vitamin D and COVID-19: don't forget the vitamin D binding protein.|pdf=|usr=}} {{tp|p=32423954|t=2020. Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.|pdf=|usr=}} {{tp|p=32496210|t=2020. Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-alpha1b for COVID-19.|pdf=|usr=}} {{tp|p=32493028|t=2020. Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients.|pdf=|usr=}} {{tp|p=32362105|t=2020. What information can I share with my patients about nutrition during COVID-19?|pdf=|usr=}} {{tp|p=32510142|t=2020. alpha-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.|pdf=|usr=}} {{tp|p=32407491|t=2020. iBioProVis: Interactive Visualization and Analysis of Compound Bioactivity Space.|pdf=|usr=}} {{tp|p=32457999|t=2020. Tocilizumab not associated with increased infection risk after CAR T - Implications for COVID-19?|pdf=|usr=}} {{tp|p=32403134|t=2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.|pdf=|usr=}} {{tp|p=32430461|t=2020. Lack of efficacy of hydroxychloroquine in covid-19.|pdf=|usr=}} {{tp|p=32503805|t=2020. Covid-19: Hydroxychloroquine was ineffective as postexposure prophylaxis, study finds.|pdf=|usr=}} {{tp|p=32487664|t=2020. Covid-19: 146 researchers raise concerns over chloroquine study that halted WHO trial.|pdf=|usr=}} {{tp|p=32269046|t=2020. Chloroquine and hydroxychloroquine in covid-19.|pdf=|usr=}} {{tp|p=32345591|t=2020. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials.|pdf=|usr=}} {{tp|p=32303505|t=2020. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear.|pdf=|usr=}} {{tp|p=32407551|t=2020. Interrogation of the safety and efficacy of home-use light-based devices.|pdf=|usr=}} {{tp|p=32480422|t=2020. Interleukin-6 Blockade Treatment for COVID-19 associated Cytokine Release Syndrome in a Patient with Poorly Controlled Chronic Myeloid Leukaemia.|pdf=|usr=}} {{tp|p=32480418|t=2020. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of severe COVID-19 patients.|pdf=|usr=}} {{tp|p=32415690|t=2020. Acute chloroquine poisoning: A comprehensive experimental toxicology assessment of the role of diazepam.|pdf=|usr=}} {{tp|p=32498751|t=2020. Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps.|pdf=|usr=}} {{tp|p=32498742|t=2020. SARS-CoV-2 (COVID-19) Vaccine Development and Production: An Ethical Way Forward.|pdf=|usr=}} {{tp|p=32429705|t=2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.|pdf=|usr=}} {{tp|p=32436730|t=2020. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.|pdf=|usr=}} {{tp|p=32347743|t=2020. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.|pdf=|usr=}} {{tp|p=32412788|t=2020. beta-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.|pdf=|usr=}} {{tp|p=32501756|t=2020. Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19.|pdf=|usr=}} {{tp|p=32267732|t=2020. Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.|pdf=|usr=}} {{tp|p=32503806|t=2020. The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic.|pdf=|usr=}} {{tp|p=32474583|t=2020. In Reply: COVID-19: An Argument for Rapid Access to Laboratory Data Warehouses.|pdf=|usr=}} {{tp|p=32459003|t=2020. A role for retinoids in the treatment of COVID-19?|pdf=|usr=}} {{tp|p=32474576|t=2020. Dose Optimization of Hydroxychloroquine for COVID-19: Do Blood Concentrations Matter?|pdf=|usr=}} {{tp|p=32459832|t=2020. Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.|pdf=|usr=}} {{tp|p=32442287|t=2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.|pdf=|usr=}} {{tp|p=32435791|t=2020. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients.|pdf=|usr=}} {{tp|p=32427279|t=2020. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19.|pdf=|usr=}} {{tp|p=32497168|t=2020. On setting expectations for a SARS-CoV-2 Vaccine.|pdf=|usr=}} {{tp|p=32492123|t=2020. The Importance of Advancing SARS-CoV-2 Vaccines in Children.|pdf=|usr=}} {{tp|p=32503801|t=2020. Does vitamin D deficiency increase the severity of COVID-19?|pdf=|usr=}} {{tp|p=32341077|t=2020. Nutritional status and COVID-19: an opportunity for lasting change?|pdf=|usr=}} {{tp|p=32303497|t=2020. Chloroquine and COVID-19 - a potential game changer?|pdf=|usr=}} {{tp|p=32498131|t=2020. Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic.|pdf=|usr=}} {{tp|p=32488861|t=2020. Applied Clinical Pharmacology in a Crisis - Interleukin-6 Axis Blockade and COVID-19.|pdf=|usr=}} {{tp|p=32350861|t=2020. COVID-19: A Defining Moment for Clinical Pharmacology?|pdf=|usr=}} {{tp|p=32442315|t=2020. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.|pdf=|usr=}} {{tp|p=32237918|t=2020. Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution.|pdf=|usr=}} {{tp|p=32475019|t=2020. Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.|pdf=|usr=}} {{tp|p=32420691|t=2020. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.|pdf=|usr=}} {{tp|p=32212378|t=2020. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders.|pdf=|usr=}} {{tp|p=32406927|t=2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.|pdf=|usr=}} {{tp|p=32284037|t=2020. Perspective on the COVID-19 Coronavirus Outbreak.|pdf=|usr=}} {{tp|p=32174284|t=2020. A Generic Computer-Assisted Four-Pronged Approach for the Management of Emerging Global Pathogens: Some Comments on COVID-19.|pdf=|usr=}} {{tp|p=32400323|t=2020. In vitro data of current therapies for SARS-CoV-2.|pdf=|usr=}} {{tp|p=32427000|t=2020. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19.|pdf=|usr=}} {{tp|p=32436829|t=2020. Triazavirin - Potential inhibitor for 2019-nCoV Coronavirus M protease: A DFT study.|pdf=|usr=}} {{tp|p=32487877|t=2020. Editorial: Challenges and Insights amidst the Covid-19 pandemic: Nutrition, the immune system and disease risk.|pdf=|usr=}} {{tp|p=32487876|t=2020. Nutrition in times of Covid-19, how to trust the deluge of scientific information.|pdf=|usr=}} {{tp|p=32479246|t=2020. Mesenchymal Stem Cell-based Therapy for COVID-19: Possibility and Potential.|pdf=|usr=}} {{tp|p=32416679|t=2020. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.|pdf=|usr=}} {{tp|p=32394841|t=2020. COVID-19: An Update on Clinical Trials.|pdf=|usr=}} {{tp|p=32282303|t=2020. Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.|pdf=|usr=}} {{tp|p=32475041|t=2020. Potential role of Anti-IL-17 in COVID-19 treatment.|pdf=|usr=}} {{tp|p=32473070|t=2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?|pdf=|usr=}} {{tp|p=32510814|t=2020. Omalizumab and COVID19 Treatment: Could It Help?|pdf=|usr=}} {{tp|p=32510734|t=2020. Azithromycin and COVID-19Prompt Early Use at First Signs of this Infection in Adults and Children An Approach Worthy of Consideration.|pdf=|usr=}} {{tp|p=32510719|t=2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.|pdf=|usr=}} {{tp|p=32500633|t=2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.|pdf=|usr=}} {{tp|p=32419517|t=2020. Emerging therapies for COVID-19 pneumonia.|pdf=|usr=}} {{tp|p=32429703|t=2020. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.|pdf=|usr=}} {{tp|p=32419524|t=2020. Old and re-purposed drugs for the treatment of COVID-19.|pdf=|usr=}} {{tp|p=32223349|t=2020. How could artificial intelligence aid in the fight against coronavirus?|pdf=|usr=}} {{tp|p=32490453|t=2020. Luminescent silicon nanostructures and COVID-19.|pdf=|usr=}} {{tp|p=32500928|t=2020. COVID-19 breakthroughs: separating fact from fiction.|pdf=|usr=}}
PMC7265850 449. Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy.
{{tp|p=32505474|t=2020. Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy.|pdf=|usr=}} {{tp|p=32419212|t=2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?|pdf=|usr=}} {{tp|p=32505362|t=2020. Investigate Oral Zinc as a Prophylactic Treatment for Those at Risk for COVID-19.|pdf=|usr=}} {{tp|p=32401673|t=2020. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.|pdf=|usr=}}
453. Evaluation of the Adjuvant Efficacy of Natural Herbal Medicine on COVID-19: A Retrospective Matched Case-Control Study.
461. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.
463. Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.
467. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al.
{{tp|p=32420751|t=2020. Evaluation of the Adjuvant Efficacy of Natural Herbal Medicine on COVID-19: A Retrospective Matched Case-Control Study.|pdf=|usr=}} {{tp|p=32428965|t=2020. Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries.|pdf=|usr=}} {{tp|p=32479158|t=2020. Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?|pdf=|usr=}} {{tp|p=32464083|t=2020. P-selectin blockade in COVID-19-related ARDS.|pdf=|usr=}} {{tp|p=32437628|t=2020. COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?|pdf=|usr=}} {{tp|p=32476261|t=2020. Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2.|pdf=|usr=}} {{tp|p=32458795|t=2020. Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2.|pdf=|usr=}} {{tp|p=32446312|t=2020. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis.|pdf=|usr=}} {{tp|p=32503855|t=2020. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.|pdf=|usr=}} {{tp|p=32503853|t=2020. COVID-19 infection in a patient with FMF: does colchicine have a protective effect?|pdf=|usr=}} {{tp|p=32327429|t=2020. Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.|pdf=|usr=}} {{tp|p=32295788|t=2020. Does hydroxychloroquine prevent the transmission of COVID-19?|pdf=|usr=}} {{tp|p=32295786|t=2020. Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist.|pdf=|usr=}} {{tp|p=32345618|t=2020. Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev et al.|pdf=|usr=}} {{tp|p=32340978|t=2020. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al.|pdf=|usr=}} {{tp|p=32321722|t=2020. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic.|pdf=|usr=}} {{tp|p=32317316|t=2020. Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?|pdf=|usr=}} {{tp|p=32317315|t=2020. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?|pdf=|usr=}}
